CardioThoracic Systems Looking To Break Even In Fourth Quarter 1999
This article was originally published in The Gray Sheet
CardioThoracic Systems' forecast of breaking even by year-end is based on increasing physician acceptance of minimally invasive cardiac surgery products in the second quarter and additional approvals expected in the latter half of the year, CEO Richard Ferrari told analysts during a July 21 teleconference.
You may also be interested in...
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.